Overview

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This single center study will help determine the absorption, metabolism, and excretion of LBH589 and to assess the safety and efficacy of LBH589 in advanced cancer patients for whom no standard therapy exists.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Panobinostat